relafen การใช้

• And she takes Relafen for her arthritis.
• However, results for the arthritis treatment Relafen lagged in the face of strong competition.
• I go to an arthritis specialist who gives me Relafen, which is the only anti-inflammatory I can take.
• GlaxoSmithKline has said that the total legal charge of about US $ 403 million includes provisions for settled and outstanding Relafen cases.
• If you need stronger prescription NSAIDS, ask your doctor about newer types like Relafen or Disalcid, which may be less toxic to your stomach.
• On Saturday, GlaxoSmithKline said it would pay US $ 175 million to settle a class-action lawsuit brought on behalf of wholesalers of Relafen.
• Analysts said they were favorably impressed with new product sales, including those of antidepressant Paxil, arthritis treatment Relafen, and Famvir, a herpes drug.
• "GSK continues to believe that its actions were appropriate in obtaining and enforcing its patent for Relafen, " the company said in a statement.
• GlaxoSmithKline was sued by consumers, health plans and pharmacies who alleged that the company tried to block cheaper generic alternatives to nonsteroidal Relafen, an arthritis medicine.
• It credited strong sales of Paxil, also called Seroxat, an antidepressant; Relafen, or Relafex, an arthritis treatment; and Kytril, a nausea treatment.
• Sales of Relafen, an arthritis treatment, increased 45 percent to 75 million pounds in the quarter, while sales of Famvir increased 72 percent to 14 million pounds.
• Drug manufacturer GlaxoSmithKline PLC will pay $ 175 million to settle a class-action lawsuit brought on behalf of wholesalers of the company's anti-inflammatory drug Relafen.
• London-based GlaxoSmithKline was sued by consumers, health plans and pharmacies who alleged that the company tried to block cheaper generic alternatives to nonsteroidal Relafen, an arthritis medicine.
• The company saw legal costs in the fourth quarter reach 223 million pounds ( US $ 403 million ) relating to antitrust litigation in the United States regarding its anti-inflammatory drug Relafen.
• Sales of Relafen, an arthritis treatment, increased 45 percent to 75 million pounds in the quarter, while sales of Famvir, an antiherpes medication, increased 72 percent to 14 million pounds.
• But new products, including Paxil, an antidepressant, Relafen for arthritis, and Kytril, to help overcome nausea during chemotherapy for cancer, rose by 83 percent to $ 341 million in the period.
• GlaxoSmithKline said its financial results for the fourth quarter, scheduled to be announced Thursday, will include a legal charge of about $ 403 million, including provisions for settled and outstanding Relafen cases . _ _=
• They are Dermatop ( Hoechst Marion Roussel ); Penetrex ( Rhone-Poulenc-Rorer ); Cardiogen-82 ( Bristol-Myers Squibb ); Nimotap ( Bayer AG ), and Relafen ( SmithKline Beecham ).
• The company said newer pharmaceutical products, including Relafen, for arthritis; Paxil, for depression; and Kytril, for cancer treatment, increased 43 percent, offsetting the decline of anti-ulcer drug Tagamet, which lost patent protection in May, 1994.
• At issue are bills in both houses that would require the U . S . Patent and Trademark Office to determine whether the seven drugs _ Cardiogen-82, Claritin, Dermatop, Eulexin, Nimotop, Penetrex and Relafen _ should be granted additional years of patent protection.